UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026385
Receipt number R000030319
Scientific Title Tau PET imaging in patients with schizophrenia and patients with frontotemporal dementia
Date of disclosure of the study information 2017/03/27
Last modified on 2023/05/26 07:00:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Tau PET imaging in patients with schizophrenia and patients with frontotemporal dementia

Acronym

Tau imaging in patients with schizophrenia and patients with frontotemporal dementia

Scientific Title

Tau PET imaging in patients with schizophrenia and patients with frontotemporal dementia

Scientific Title:Acronym

Tau imaging in patients with schizophrenia and patients with frontotemporal dementia

Region

Japan


Condition

Condition

schizophrenia, frontotemporal dementia

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate common pathophysiological characteristics in schizophrenia and frontotemporal dementia

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Distribution of Tau in the brain

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

healthy controls

Interventions/Control_2

patients with schizophrenia spectrum and other psychotic disorders

Interventions/Control_3

patients with frontotemporal dementia (FTD/FTLD)

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Participants who can understand the content of this study. Each patient must meet the diagnostic criterion.

Key exclusion criteria

Subjects with severe physical, or other psychiatric diseases
Subjects with strong suicide ideation
Subjects during (probable) pregnancy or breast-feeding

Target sample size

90


Research contact person

Name of lead principal investigator

1st name Keisuke
Middle name
Last name Takahata

Organization

National Institutes for Quantum Science and Technology

Division name

Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate

Zip code

263-8555

Address

4-9-1 Anagawa, Inage-ku, Chiba

TEL

+81-43-206-3251

Email

takahata.keisuke@qst.go.jp


Public contact

Name of contact person

1st name Kazuko
Middle name
Last name Suzuki

Organization

National Institutes for Quantum Science and Technology

Division name

Clinical Research Section

Zip code

263-8555

Address

4-9-1 Anagawa, Inage-ku, Chiba

TEL

+81-43-206-3251

Homepage URL


Email

suzuki.kazuko@qst.go.jp


Sponsor or person

Institute

Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate
National Institutes for Quantum Science and Technology

Institute

Department

Personal name



Funding Source

Organization

Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate
National Institutes for Quantum Science and Technology

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of the National Institutes for Quantum Science and Technology

Address

4-9-1 Anagawa, Inage-ku, Chiba

Tel

043-206-4709

Email

helsinki@qst.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 03 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Suspended

Date of protocol fixation

2017 Year 02 Month 28 Day

Date of IRB

2017 Year 02 Month 28 Day

Anticipated trial start date

2017 Year 04 Month 11 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 03 Month 03 Day

Last modified on

2023 Year 05 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030319


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name